Needham & Company Reiterates Cytokinetics (CYTK) at Buy, Sees no Impact from METEORIC-HF Fail on Potential FDA Approval
Tweet Send to a Friend
Needham & Company analyst Serge Belanger reiterated a Buy rating and $52.00 price target on Cytokinetics (NASDAQ: CYTK), following news ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
